Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$30.84 -1.4%	$30.85	$22.90 ▼ $36.45	$5.09B	0.51	1.77 million shs	1.12 million shs
BCRX BioCryst Pharmaceuticals	$10.06 -2.7%	$7.96	$5.35 ▼ $11.11	$2.11B	1.08	3.01 million shs	6.12 million shs
IONS Ionis Pharmaceuticals	$32.53 -3.0%	$30.55	$23.95 ▼ $52.34	$5.18B	0.15	1.57 million shs	1.36 million shs
MNKD MannKind	$4.72 -1.9%	$4.88	$4.34 ▼ $7.63	$1.43B	1.14	2.39 million shs	2.46 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	+3.71%	-0.41%	+15.81%	-2.16%	+30.02%
BCRX BioCryst Pharmaceuticals	+3.61%	-6.26%	+51.61%	+15.02%	+94.36%
IONS Ionis Pharmaceuticals	+3.94%	-0.36%	+20.18%	+6.17%	-14.20%
MNKD MannKind	+5.48%	-3.02%	+3.22%	-13.80%	+11.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALKS Alkermes	4.3356 of 5 stars	3.3	1.0	4.2	3.0	2.5	1.9
BCRX BioCryst Pharmaceuticals	4.6761 of 5 stars	4.4	3.0	4.2	3.8	1.7	0.6
IONS Ionis Pharmaceuticals	4.5152 of 5 stars	4.3	1.0	3.0	4.2	3.3	0.6
MNKD MannKind	2.8433 of 5 stars	3.6	1.0	0.0	3.5	0.8	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.67	Moderate Buy	$38.33	24.30% Upside
BCRX BioCryst Pharmaceuticals	2.89	Moderate Buy	$16.56	64.57% Upside
IONS Ionis Pharmaceuticals	2.65	Moderate Buy	$56.67	74.20% Upside
MNKD MannKind	3.25	Buy	$10.00	111.86% Upside

Current Analyst Ratings Breakdown

Latest MNKD, IONS, ALKS, and BCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/7/2025	BCRX BioCryst Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $11.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $17.00
5/6/2025	BCRX BioCryst Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/2/2025	ALKS Alkermes	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
5/2/2025	ALKS Alkermes	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$39.00 ➝ $40.00
5/2/2025	ALKS Alkermes	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$38.00 ➝ $41.00
5/1/2025	IONS Ionis Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$65.00 ➝ $64.00
5/1/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $50.00
4/30/2025	IONS Ionis Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $55.00

(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.51B	3.36	$2.32 per share	13.32	$9.05 per share	3.41
BCRX BioCryst Pharmaceuticals	$503.49M	4.18	N/A	N/A	($2.22) per share	-4.53
IONS Ionis Pharmaceuticals	$717.25M	7.22	N/A	N/A	$3.70 per share	8.79
MNKD MannKind	$297.60M	4.82	N/A	N/A	($0.91) per share	-5.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$367.07M	$2.09	14.21	22.51	2.20	23.57%	30.80%	19.09%	7/23/2025 (Estimated)
BCRX BioCryst Pharmaceuticals	-$226.54M	-$0.26	N/A	N/A	N/A	-30.01%	N/A	-24.06%	N/A
IONS Ionis Pharmaceuticals	-$366.29M	-$2.99	N/A	N/A	N/A	-64.25%	-100.05%	-15.70%	N/A
MNKD MannKind	-$11.94M	$0.10	67.43	20.52	N/A	8.07%	-17.74%	8.68%	N/A

Latest MNKD, IONS, ALKS, and BCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	MNKD MannKind	$0.03	$0.04	+$0.01	$0.04	$75.86 million	$78.35 million
5/1/2025	Q1 2025	ALKS Alkermes	$0.32	$0.13	-$0.19	$0.13	$307.53 million	$306.51 million
4/30/2025	Q1 2025	IONS Ionis Pharmaceuticals	-$1.07	-$0.93	+$0.14	-$0.93	$144.31 million	$132.00 million
2/26/2025	Q4 2024	MNKD MannKind	$0.03	$0.03	N/A	$0.03	$74.99 million	$76.78 million
2/24/2025	Q4 2024	BCRX BioCryst Pharmaceuticals	-$0.07	-$0.13	-$0.06	-$0.13	$126.64 million	$131.50 million
2/19/2025	Q4 2024	IONS Ionis Pharmaceuticals	-$1.12	-$0.66	+$0.46	-$0.66	$140.97 million	$227.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	N/A	3.04	2.65
BCRX BioCryst Pharmaceuticals	N/A	2.78	2.73
IONS Ionis Pharmaceuticals	2.12	8.47	8.82
MNKD MannKind	N/A	4.54	4.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
BCRX BioCryst Pharmaceuticals	85.88%
IONS Ionis Pharmaceuticals	93.86%
MNKD MannKind	49.55%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.40%
BCRX BioCryst Pharmaceuticals	4.80%
IONS Ionis Pharmaceuticals	2.60%
MNKD MannKind	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,280	164.90 million	154.66 million	Optionable
BCRX BioCryst Pharmaceuticals	530	209.25 million	197.19 million	Optionable
IONS Ionis Pharmaceuticals	800	159.16 million	153.62 million	Optionable
MNKD MannKind	400	303.85 million	267.51 million	Optionable

MNKD, IONS, ALKS, and BCRX Headlines

Recent News About These Companies

MannKind to Present at Upcoming Investor Conferences

May 13 at 4:05 PM | globenewswire.com

Promising Clinical Data and Market Potential Drive Buy Rating for MannKind’s Afrezza

May 12 at 11:16 AM | tipranks.com

Graham Capital Management L.P. Makes New Investment in MannKind Co. (NASDAQ:MNKD)

May 12 at 6:35 AM | marketbeat.com

MannKind Co. (NASDAQ:MNKD) Shares Sold by Tudor Investment Corp ET AL

May 11 at 4:32 AM | marketbeat.com

Dimensional Fund Advisors LP Acquires 855,261 Shares of MannKind Co. (NASDAQ:MNKD)

May 10 at 3:44 AM | marketbeat.com

MannKind Corporation (MNKD): Among the Best Cancer Stocks to Invest in for Long-Term Gain

May 9, 2025 | insidermonkey.com

Schonfeld Strategic Advisors LLC Trims Stock Position in MannKind Co. (NASDAQ:MNKD)

May 9, 2025 | marketbeat.com

Decoding MannKind Corp (MNKD): A Strategic SWOT Insight

May 9, 2025 | gurufocus.com

MannKind’s Promising Growth and Strategic Advancements Justify Buy Rating

May 8, 2025 | tipranks.com

MannKind’s Promising Growth Potential: Buy Rating Backed by Strong Financials and Strategic Advancements

May 8, 2025 | tipranks.com

MannKind Corporation (MNKD) Q1 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates

May 8, 2025 | zacks.com

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025 | globenewswire.com

MannKind Q1 2025 Earnings Preview

May 7, 2025 | msn.com

Freestone Grove Partners LP Makes New Investment in MannKind Co. (NASDAQ:MNKD)

May 7, 2025 | marketbeat.com

MannKind Co. (NASDAQ:MNKD) Receives Consensus Rating of "Buy" from Analysts

May 6, 2025 | marketbeat.com

MannKind (MNKD) to Release Earnings on Thursday

May 5, 2025 | marketbeat.com

Manatuck Hill Partners LLC Acquires 75,000 Shares of MannKind Co. (NASDAQ:MNKD)

May 4, 2025 | marketbeat.com

Voya Investment Management LLC Trims Position in MannKind Co. (NASDAQ:MNKD)

May 4, 2025 | marketbeat.com

First Trust Advisors LP Makes New Investment in MannKind Co. (NASDAQ:MNKD)

May 4, 2025 | marketbeat.com

Apollo Management Holdings L.P. Sells 300,000 Shares of MannKind Co. (NASDAQ:MNKD)

May 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Rocket Lab Braces for Q1 Earnings Amid Soaring Expectations
By Ryan Hasson | May 5, 2025
View Rocket Lab Braces for Q1 Earnings Amid Soaring Expectations
NVIDIA Stock Surges on Bullish News: How High Could It Climb?
By Thomas Hughes | May 13, 2025
View NVIDIA Stock Surges on Bullish News: How High Could It Climb?
Time to Buy Alibaba and PDD After Tariff Exemptions?
By Gabriel Osorio-Mazilli | April 17, 2025
View Time to Buy Alibaba and PDD After Tariff Exemptions?
AT&T, Verizon & T-Mobile: Who Won the Big 3 Telecom Battle in Q1?
By Leo Miller | May 1, 2025
View AT&T, Verizon & T-Mobile: Who Won the Big 3 Telecom Battle in Q1?
Why Institutions Are Buying Super Micro Computer Stock Again
By Gabriel Osorio-Mazilli | April 28, 2025
View Why Institutions Are Buying Super Micro Computer Stock Again

MNKD, IONS, ALKS, and BCRX Company Descriptions

Alkermes NASDAQ:ALKS

$30.84 -0.43 (-1.38%)

As of 04:00 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

BioCryst Pharmaceuticals NASDAQ:BCRX

$10.06 -0.28 (-2.71%)

As of 04:00 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Ionis Pharmaceuticals NASDAQ:IONS

$32.53 -1.00 (-2.98%)

As of 04:00 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

MannKind NASDAQ:MNKD

$4.72 -0.09 (-1.87%)

As of 04:00 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time